WA-KYMETA
World-leading flat-panel satellite antenna company, Kymeta (www.kymetacorp.com), announced today at SATELLITE 2024 that the Osprey u8 HGL, a hybrid geostationary/low Earth orbit (GEO/LEO/LTE) terminal purpose-built for military users, is shipping out of their facility in Woodinville, Washington. This marks the first commercially available multi-orbit terminal and the first multi-orbit terminal on Eutelsat OneWeb’s LEO network. Kymeta announced the official launch in October last year and is fulfilling a backlog of orders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318848741/en/
Kymeta - The Future of Military SATCOM is now. On the move GEO-LEO-LTE from one single terminal - Osprey u8 HGL (Graphic: Business Wire)
In February, the Kymeta team demonstrated in the field the capabilities of the new Osprey u8 HGL delivering resilient, auto-PACE ready communications for the armed forces to meet the demands of challenging and rugged military environments. The multi-orbit, multi-network capabilities of the Osprey u8 HGL terminal will offer even greater availability, while being durable, low power consuming, having low visibility, and easy to use.
The Osprey u8 HGL includes a field swappable modem cartridge and a OneWeb modem to enable connectivity with the Eutelsat OneWeb LEO network. At launch an iDirect 950mp cartridge is available enabling TRANSEC services over GEO. Other cartridge configurations will be available soon enabling end users to customize their terminal configuration based on their mission needs.
Initial feedback was overwhelmingly positive, with one military member stating: “This is everything we’ve been looking for in a terminal, form function and features. The LEO to GEO switching far exceeded our expectations. It’s amazing that Kymeta is already delivering on the community’s urgent need for multi-orbit SATCOM.”
Others in attendance at Army field demonstrations commented, “I cannot wait to get started with these!” and “Wow! It tracks satellites over some very difficult terrain.”
“The Kymeta Osprey HGL has a unique capability to address government requirements in support of government PACE plans,” said Ian Canning, Chief Operating Officer, OneWeb Technologies. “The Osprey supports multi-network/orbit requirements through the concurrent LTE/satellite configuration with the added benefit of now being able to add OneWeb LEO capabilities.”
Jon Osler, Senior Vice President Global Sales and Services of Kymeta, commented: “In the contemporary military landscape, mobile connectivity has become indispensable for achieving success. Unlike any other sector, the military relies heavily on dependable, adaptable, and resilient on-the-go communication systems to fulfill its operational and training needs. We take pride in our longstanding partnership with the military, delivering cutting-edge solutions that meet and exceed expectations.”
This milestone further establishes Kymeta as the leader in the multi-X revolution. Attendees of SATELLITE 2024 in Washington, DC, March 18– 20 are encouraged to visit Kymeta’s meeting room 156 to see the Osprey u8 HGL in person and to speak with a member of the Kymeta team.
About Kymeta
Kymeta is the industry leader in flat panel satellite antennas, providing purpose-built solutions across a variety of enterprise and military applications and unlocking the commercial value of space to address the vast, unmet demand for ubiquitous broadband and truly mobile connectivity for customers around the world. Its innovative metasurface technology, coupled with a software-first approach, delivers the first commercially available, metamaterial-based and electronically steered flat panel satellite antenna. Kymeta’s low-cost, low power and high throughput solutions make it easy to connect on the move or while stationary – for any vehicle, vessel, aircraft, or fixed platform – enabling industries on earth to transform their operations by harnessing capacity in space.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318848741/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom